SWP
VRTX icon

Stratos Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Stratos Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.47M Hold
3,299
– – 0.02% 658
2025
Q4 		$1.5M Buy
3,299
+207
+7% +$89.2K 0.02% 631
2025
Q3 		$1.21M Sell
3,092
-109
-3% -$45.6K 0.01% 678
2025
Q2 		$1.43M Sell
3,201
-1,083
-25% -$499K 0.02% 589
2025
Q1 		$2.08M Sell
4,284
-1,097
-20% -$511K 0.03% 444
2024
Q4 		$2.17M Sell
5,381
-274
-5% -$127K 0.03% 453
2024
Q3 		$2.63M Sell
5,655
-62
-1% -$29.8K 0.04% 394
2024
Q2 		$2.68M Buy
5,717
+434
+8% +$188K 0.04% 375
2024
Q1 		$2.21M Buy
5,283
+2,157
+69% +$912K 0.04% 423
2023
Q4 		$1.27M Buy
3,126
+111
+4% +$41K 0.02% 538
2023
Q3 		$1.05M Sell
3,015
-344
-10% -$120K 0.02% 556
2023
Q2 		$1.18M Buy
3,359
+237
+8% +$79.9K 0.03% 487
2023
Q1 		$984K Sell
3,122
-838
-21% -$251K 0.03% 488
2022
Q4 		$1.14M Buy
3,960
+681
+21% +$208K 0.03% 476
2022
Q3 		$949K Buy
3,279
+205
+7% +$59K 0.03% 494
2022
Q2 		$866K Buy
3,074
+196
+7% +$52.5K 0.02% 553
2022
Q1 		$751K Buy
2,878
+228
+9% +$54.1K 0.02% 647
2021
Q4 		$582K Sell
2,650
-283
-10% -$55K 0.01% 756
2021
Q3 		$532K Buy
2,933
+543
+23% +$106K 0.01% 720
2021
Q2 		$482K Sell
2,390
-28
-1% -$5.86K 0.01% 783
2021
Q1 		$520K Buy
2,418
+946
+64% +$208K 0.01% 709
2020
Q4 		$348K Buy
1,472
+78
+6% +$17.9K 0.01% 795
2020
Q3 		$379K Sell
1,394
-641
-31% -$177K 0.01% 704
2020
Q2 		$591K Buy
2,035
+1,086
+114% +$294K 0.02% 538
2020
Q1 		$226K Buy
+949
New +$218K 0.01% 772
2018
Q4 		– Sell
-640
Closed -$123K – 2467
2018
Q3 		$123K Buy
+640
New +$114K 0.01% 1036
2018
Q2 		– Sell
-764
Closed -$125K – 2556
2018
Q1 		$125K Sell
764
-257
-25% -$42K 0.01% 1080
2017
Q4 		$153K Buy
+1,021
New +$151K 0.01% 984

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Stratos Wealth Partners's VRTX Position: Q1 2026 in Review

Stratos Wealth Partners held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 3,299 shares worth $1.47M. The position accounts for 0.02% of the portfolio, ranked #658.

Stratos Wealth Partners first reported a position in VRTX in Q4 2017 and has held it in 28 quarters since. The position peaked at $2.68M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Stratos Wealth Partners held 3,299 shares of Vertex Pharmaceuticals worth $1.47M as of Q1 2026.
  • Stratos Wealth Partners left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.02% of Stratos Wealth Partners's portfolio in Q1 2026, its #658 holding.
  • Stratos Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 28 quarters since.
  • Stratos Wealth Partners's Vertex Pharmaceuticals position peaked at $2.68M in Q2 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Stratos Wealth Partners's 13F filing for Q1 2026, filed 28 Apr 2026.